title: Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
abstract: The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial is the first angiographic clinical trial to be designed to test whether an agent can slow or even reverse the progression of early coronary atherosclerosis in patients with documented disease. In addition, a subset of patients are undergoing carotid ultrasound examinations, providing a unique opportunity to assess and correlate disease progression in 2 arterial beds.
authors.affiliation: Department of Public Health Sciences, The Bowman Gray School of Medicine, Winston Salem, North Carolina 27157, USA.
authors.forename: R P
authors.initials: RP
authors.lastname: Byington
authors.forename: M E
authors.initials: ME
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Herrington
authors.forename: W
authors.initials: W
authors.lastname: Riley
authors.forename: B
authors.initials: B
authors.lastname: Pitt
authors.forename: C D
authors.initials: CD
authors.lastname: Furberg
authors.forename: D B
authors.initials: DB
authors.lastname: Hunninghake
authors.forename: G B
authors.initials: GB
authors.lastname: Mancini
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000517:prevention & control*; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D017311:Amlodipine